<DOC>
	<DOCNO>NCT01683604</DOCNO>
	<brief_summary>This multi-center , observational study evaluate treatment pattern clinical practice , efficacy safety tocilizumab participant rheumatoid arthritis ( RA ) inadequate response ( intolerant ) treatment non-biological disease-modifying anti-rheumatic drug ( DMARDs ) one biological agent . Data collect eligible participant initiate tocilizumab treatment treat physician accord approve label 6 month start treatment .</brief_summary>
	<brief_title>Observational Study Tocilizumab Participants With Rheumatoid Arthritis Australia</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Severe RA . Inadequate response ( intolerant ) nonbiological DMARDs one biologic agent Participants initiate treatment tocilizumab physician 's decision ( accordance local label ) , include participant start treatment tocilizumab within 8 week prior enrolment visit . Tocilizumab treatment 8 week prior enrolment visit . Previous tocilizumab treatment clinical trial compassionate use . Enrolled ongoing clinical trial and/or treatment investigational agent within 4 week ( 5 halflives investigational agent , whichever long ) start treatment tocilizumab . History autoimmune disease joint inflammatory disease RA .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>